Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yiqi Wenyang Sanhan Formula is a Traditional Chinese Medicine (TCM) herbal preparation developed for the management of combined allergic rhinitis and asthma syndrome (CARAS), particularly during the remission stage in patients with a Yang-deficiency syndrome constitution. The formula is designed based on the TCM principles of "Yiqi" (supplementing Qi), "Wenyang" (warming Yang), and "Sanhan" (dispersing cold) to address the underlying constitutional imbalances that lead to recurrent allergic airway inflammation. It is typically used as an internal therapy in conjunction with external treatments like acupoint application. The goal of the intervention is to regulate the body's immune state, reduce the risk of acute exacerbations, and improve the long-term quality of life for patients with chronic allergic conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yiqi Wenyang Sanhan Formula.